Abstract:ID 92395 Poster Board 511 Opioid Use Disorder (OUD) is a chronic, relapsing disease that, despite our best research efforts, has become a worsening public health crisis. Currently, the medications to treat OUD belong to the opioid class of drugs and, therefore, continue to interact directly with opioid receptors. While these medications are safe and effective for the cessation of opioids with higher abuse potentials, there is still a need for effective non-opioid receptor-targeting therapeutics. Exploring novel non-opioid targets is necessary to overcome this barrier. One such non-opioid target we are currently investigating is the calcitonin gene-related peptide (CGRP) system, particularly CGRP-expressing neurons in the parabrachial nucleus (CGRP PBN ). These neurons have been well studied in itch and pain and are known to project to brain regions implicated in opioid reward and withdrawal. Previous studies in our lab have found that CGRP PBN activity decreases during opioid taking and increases during opioid withdrawal. To further characterize the behavioral role of CGRP PBN neurons in opioid withdrawal, Calca-Cre transgenic mice received viral injections into the PBN containing an inhibitory DREADD (hm4Di), and two weeks later, mice were implanted with 2x25 mg morphine pellets. After five days, morphine withdrawal was induced by removing the pellets. Mice were administered either clozapine-N-oxide (CNO) (3 mg/kg, I.P.) or vehicle (saline, I.P.) 5.5 hours post pellet removal, and behavior was recorded at 6 and 24 hours post pellet removal. Two experimenters scored videos for jumping and wet dog shakes. Those mice injected with CNO showed fewer wet-dog shakes at the 6-hour time than vehicle-injected controls. We next sought to characterize the behavioral role of CGRP PBN neurons in opioid taking. In this experiment, morphine intravenous self-administration (IVSA) was used. Calca-Cre transgenic mice received viral injections into the PBN containing either an inhibitory DREADD (hm4Di) or a control mCherry vector and, two weeks later, were implanted with jugular catheters. Subsequently, operant responding for intravenous morphine was established. After 12 daily sessions, mice were administered CNO (3 mg/kg, I.P.) or vehicle (saline, I.P.) and allowed to respond for morphine. CGRP PBN inhibition reduced morphine intake in hm4Di-injected animals, while those with a control virus maintained their previous levels of morphine intake. Decreases in morphine intake were maintained 24 hours after CNO administration but returned to previous baseline levels at 48 hours. These results suggest that CGRP PBN neurons play a role in the behavioral consequences of both opioid reinforcement and withdrawal. CGRP receptor inhibitors are FDA-approved for the treatment of migraine and exist in both short and long-lasting formulations. By leveraging these available medications for the off-label purpose of treating OUD, we may be able to determine the translational potential of these preclinical findings and, therefore, expand our therapeutic arsenal for long-term maintenance of opioid abstinence and relapse.

Effects of polyinosinic-polycytidylic acid (Poly I:C) on naloxone-precipitated withdrawal in morphine-dependent mice.

Synthetic double-stranded RNA polyinosinic-polycytidylic acid augments morphine-induced conditioned place preference in rats.

Influence Of Clonidine And Ketamine On M-Rna Expression In A Model Of Opioid-Induced Hyperalgesia In Mice

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

Interferon-Alpha Reinstates Morphine-Conditioned Place Preference Through Opioid Receptors in Rats

Effects of Aquaporin 4 Deficiency on the Expression of Spinal PKCα, PKCγ and C-Fos in Naloxone-Precipitated Morphine Withdrawal Mice.

Inhibition of Parabrachial CGRP Neurons Reduces Morphine Reinforcement and Withdrawal

Effect of Morphine Dependence and Abstinence on the Expression of B-cell Lymphomal-2 in Sprague-Dawley Rats

Effects of 5-HT1A Receptor Antagonist and 5-HT2A Receptor Agonist on Morphine Withdrawal

Effect of Intrathecal Morphine and Electro-Acupuncture on Cellular Immune Function of Rats and Increment of Mu-Opioid Receptor Mrna Expression in PAG Following Intrathecal Morphine.

Spinal kappa-opioid system plays an important role in suppressing morphine withdrawal syndrome in the rat

Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice

Modulation of Intrathecal Morphine-Induced Immunosuppression by Microinjection of Naloxone into Periaqueductal Gray

Blockade of 5-Hydroxytryptamine 2A Receptor Attenuates Precipitation of Naloxone-Induced Withdrawal Symptoms in Opioid-Exposed Mice

Morphine and Heroin Differentially Modulate in Vivo Hippocampal LTP in Opiate-Dependent Rat

Proteomic analysis of the nucleus accumbens in rhesus monkeys of morphine dependence and withdrawal intervention.

Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome

Decreased myelin-related gene expression in the nucleus accumbens during spontaneous neonatal opioid withdrawal in the absence of long-term behavioral effects in adult outbred CFW mice

Parvalbumin Interneurons of Central Amygdala Regulate the Negative Affective States and the Expression of Corticotrophin-Releasing Hormone During Morphine Withdrawal.

Immunosuppressive Effects of Dihydroetorphine, a Potent Narcotic Analgesic, in Dihydroetorphine-Dependent Mice.

Decreased Neuronal Excitability in Medial Prefrontal Cortex during Morphine Withdrawal is associated with enhanced SK channel activity and upregulation of small GTPase Rac1